This study confirmed that lornoxicam administered as a quick-release formulation in patients with acute low back pain is an effective and well tolerated analgesic, is not inferior to the equivalent formulation of diclofenac potassium in terms of onset of PAR, and provides a higher magnitude of analgesic effect with associated better global evaluation of the study medication.
The authors thank all the co-investigators for their valuafore ble contributions to the performance of this study. The coinvestigators were: E.V. Podchufarova, A.I. Isaykin, D.V. Galanov, K.S. Glushkov, T.V. Mikhailova, T.A. Skoromets, A.P. Rachin, O.M. Ustennaya, Y.V. Yurieva, V.A. Bulanova, S.B. Ossipova, A.G. Raybov, E.V. Zakhovskaya.Funding information
This study was supported by an unrestricted grant from Nycomed. The authors have no conflicts of interest directly relevant to the content of this study.
Dr P.L. Moller, International Medical Affairs, Nycomed, Langebjerg 1, 4000 Roskilde, Denmark. E-mail: firstname.lastname@example.org
Clin Drug Invest. 2006;26(5):267-277. © 2006 Adis Data Information BV
Cite this: Analgesic Efficacy and Safety of Lornoxicam Quick-Release Formulation Compared With Diclofenac Potassium - Medscape - Jun 01, 2006.